Research Funding supports researchers, clinicians, and industry worldwide in preclinical research to accelerate progress toward treatments and cures for CMT and related inherited neuropathies.
Funder: Hereditary Neuropathy Foundation
Due Dates: Rolling (LOIs and proposals; no application deadline)
Funding Amounts: Typically $50,000–$100,000 per year in direct costs; generally one year of support
Summary: Supports preclinical research worldwide to accelerate progress toward treatments and cures for Charcot-Marie-Tooth disease and related inherited neuropathies.
Key Information: Contact HNF’s Chief Scientific Officer before submitting an LOI or formal application.
The Hereditary Neuropathy Foundation (HNF) supports preclinical research aligned with its mission and key objectives, with an emphasis on advancing work as quickly as possible. HNF funds research primarily through its Therapeutic Research in Accelerated Discovery (TRIAD) program, which brings together academia, government, and industry to advance drug discovery, gene therapy, and clinical-trial readiness for Charcot-Marie-Tooth disease (CMT).
The program seeks projects with defined scientific aims, a clear rationale, measurable milestones, and a timeline connecting objectives to an experimental plan. Collaboration with companies or institutions that can advance findings or co-fund research is encouraged. HNF’s TRIAD Council evaluates full proposals, and project progress and achievement of milestones inform consideration of longer-term support.